In 2021 Clifford et al. demonstrated in murine that the use of GSK2324 a FXR agonist reduced lipid uptake as well as decreased lipogenesis, as a result hepatic steatosis was significantly reduced.151 Moreover, other FXR agonists have been used in randomized control trials as cicloflexor (GS-9674) in patients with MASH, decreasing hepatic steatosis, the transaminases in serum and the circulating BAs. This evidence concerns the gene NR1H4 and fatty liver disease.